Cargando…

High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy

BACKGROUND: Stereotactic body radiation therapy (SBRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma (BRPC/LAPC) remains controversial. Herein, we report on surgical, pathologic, and survival outcomes in BRPC/LAPC patients treated at a high‐volume institution...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Colin, Sehgal, Shuchi, Fu, Wei, Hu, Chen, Reddy, Abhinav, Thompson, Elizabeth, Hacker‐Prietz, Amy, Le, Dung, De Jesus‐Acosta, Ana, Lee, Valerie, Zheng, Lei, Laheru, Daniel A., Burns, William, Weiss, Matthew, Wolfgang, Christopher, He, Jin, Herman, Joseph M., Meyer, Jeffrey, Narang, Amol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986142/
https://www.ncbi.nlm.nih.gov/pubmed/35142085
http://dx.doi.org/10.1002/cam4.4527
Descripción
Sumario:BACKGROUND: Stereotactic body radiation therapy (SBRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma (BRPC/LAPC) remains controversial. Herein, we report on surgical, pathologic, and survival outcomes in BRPC/LAPC patients treated at a high‐volume institution with induction chemotherapy (CTX) followed by 5‐fraction SBRT. METHODS: BRPC/LAPC patients treated between 2016 and 2019 were retrospectively reviewed. Surgical and pathological outcomes were descriptively characterized. Overall survival (OS) and progression‐free survival (PFS) were analyzed using Cox proportional hazard regression. Locoregional failure and distant failure were analyzed with Fine–Gray competing risk model. RESULTS: Of 155 patients, 91 (59%) had LAPC and 64 (41%) had BRPC. Almost all were treated with induction multi‐agent CTX with either FOLFIRINOX (75%) or gemcitabine and nab‐paclitaxel (24%) for a median duration of 4.0 months (1–18 months). All received SBRT to a median dose of 33 Gy. Among 64 BRPC patients, 50 (78%) underwent resection, of whom 48 (96%) achieved margin‐negative (R0) resection. Among 91 LAPC patients, 57 (63%) underwent resection, of whom 50 (88%) achieved R0 resection. Despite the high R0 rate, 33% of patients experienced locoregional failure, which was a component of 44% of all failures. After SBRT, median OS and PFS were 18.7 and 7.7 months, respectively. After SBRT, 1‐ and 2‐year OS probabilities were 70% and 45%, whereas, from diagnosis, they were 93% and 51%. CONCLUSIONS: Although a high proportion of BRPC/LAPC patients treated with induction multi‐agent CTX followed by SBRT successfully achieved R0 resection, locoregional failure remained common, highlighting the need to continue to optimize radiation delivery in this context.